| Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines Q Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, ... Annals of medicine 54 (1), 524-540, 2022 | 351 | 2022 |
| CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances KM Maalej, M Merhi, VP Inchakalody, S Mestiri, M Alam, C Maccalli, ... Molecular Cancer 22 (1), 20, 2023 | 93 | 2023 |
| Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer A Raza, AQ Khan, VP Inchakalody, S Mestiri, ZSKM Yoosuf, T Bedhiafi, ... Journal of Experimental & Clinical Cancer Research 41 (1), 99, 2022 | 51 | 2022 |
| The potential role of vitamin C in empowering cancer immunotherapy T Bedhiafi, VP Inchakalody, Q Fernandes, S Mestiri, N Billa, S Uddin, ... Biomedicine & Pharmacotherapy 146, 112553, 2022 | 35 | 2022 |
| The role of PAK4 in the immune system and its potential implication in cancer immunotherapy A Naїja, M Merhi, V Inchakalody, Q Fernandes, S Mestiri, KS Prabhu, ... Cellular Immunology 367, 104408, 2021 | 19 | 2021 |
| Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy … M Merhi, A Raza, VP Inchakalody, KS Siveen, D Kumar, F Sahir, S Mestiri, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 12 | 2020 |
| The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling E Laplantine, C Chable-Bessia, A Oudin, J Swain, A Soria, P Merida, ... Iscience 25 (10), 2022 | 7 | 2022 |
| The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target L Al-Zaidan, S Mestiri, A Raza, M Merhi, VP Inchakalody, Q Fernandes, ... Tumor Biology 43 (1), 177-196, 2021 | 7 | 2021 |
| Chronic inflammation and cancer; the two sides of a coin Q Fernandes, VP Inchakalody, T Bedhiafi, S Mestiri, N Taib, S Uddin, ... Life Sciences, 122390, 2023 | 6 | 2023 |
| Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy N Taib, M Merhi, V Inchakalody, S Mestiri, S Hydrose, K Makni-Maalej, ... Journal of Translational Medicine 21 (1), 235, 2023 | 5 | 2023 |
| The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR) VP Inchakalody, SP Hydrose, R Krishnankutty, M Merhi, L Therachiyil, ... European Journal of Pharmacology 945, 175612, 2023 | 2 | 2023 |
| Vaccines and Immunotherapies against the Human Papillomavirus and Epstein-Barr Virus Q Fernandes, S Mestiri, T Bedhiafi, A Raza, M Merhi, S Hydrose, ... Advances in Health and Disease 60, 2022 | 1 | 2022 |
| SARS-CoV-2 S protein binding hACE2: viral entry, pathogenesis, prognosis, and potential therapeutic targets L Al-Zaidan, S Mestiri, A Raza, M Merhi, V Inchakalody, Q Fernandez, ... Preprints, 2020 | 1 | 2020 |
| The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers S Mestiri, DMA El-Ella, Q Fernandes, T Bedhiafi, S Almoghrabi, S Akbar, ... Biomedicine & Pharmacotherapy 171, 116095, 2024 | | 2024 |
| Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive … S Mestiri, M Merhi, VP Inchakalody, N Taib, MK Smatti, F Ahmad, A Raza, ... Frontiers in Immunology 14, 1061255, 2023 | | 2023 |
| Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives F Al-Ejeh, M Merhi, M Al-Muftah, Q Fernandes, L Al-Zaidan, T Bedhiafi, ... Omics approaches and technologies in COVID-19, 61-85, 2023 | | 2023 |
| 736 Treatment with decitabine (DAC) induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer N Taib, M Merhi, V Inchakalody, S Mestiri, A Raza, S Uddin, C Maccalli, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A767-A767, 2021 | | 2021 |
| 463 Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno … M Merhi, A Raza, V Inchakalody, S Kodappully, D Choubey, F Sahir, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
| Identification of a Novel Promiscuous Anti-NY-ESO-1 Immunogenic CD4+ Peptide Containing a CD8+ T-Cell Epitope Highly Present in Metastatic Gastric Cancer Responding to Combined … M Merhi, A Raza, V Inchakalody, S Sivaraman, F Panayampilly, S Mestiri, ... Annals of Oncology 30, xi41, 2019 | | 2019 |
| Jochen Mattner, University of Erlangen Nuremberg, Germany T Demberg, S Mestiri, I Schmitz, S Pfänder, N Heinen, CS Marheinecke, ... | | |
